Fenebrutinib Shows 12% Reduction in Disability Progression vs Ocrelizumab in PPMS Trial
Feb 25, 2026
Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.